Explore

Reuters Reuters
CVS raises annual profit forecast on improved drug revenues

CVS raises annual profit forecast on improved drug revenues

By Amina Niasse NEW YORK, Aug 5 (Reuters) - CVS Health on Wednesday raised its annual profit forecast to reflect a better-than-expected second quarter marked by a more profitable mix of drugs in its pharmacy business and bonus payments for its highly rated government health plans.
Reuters Reuters
CVS raises annual profit forecast on improved drug revenue

CVS raises annual profit forecast on improved drug revenue

By Amina Niasse NEW YORK, Aug 5 (Reuters) - CVS Health on Wednesday raised its annual profit forecast to reflect a better-than-expected second quarter marked by a more profitable mix of drugs in its pharmacy business and bonus payments for its highly rated government health plans.
Trendline Trendline
Merck's Q2 Earnings Exceed Expectations, Adjusts Full-Year Outlook

Merck's Q2 Earnings Exceed Expectations, Adjusts Full-Year Outlook

Merck's Q2 Earnings Exceed Expectations, Adjusts Full-Year Outlook
Trendline Trendline
SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report

SB1 Markets Recommends Buying Novo Nordisk Stock Ahead of Earnings Report
Reuters Reuters
Novo outlook hike falls flat as high Wegovy pill hopes unmet

Novo outlook hike falls flat as high Wegovy pill hopes unmet

By Stine Jacobsen and Maggie Fick COPENHAGEN, Aug 4 (Reuters) - Novo Nordisk beat second-quarter profit forecasts and raised its full-year outlook on Wednesday, but shares in the drugmaker fell 6% as investors focused on underwhelming sales of its Wegovy weight-loss pill.
Reuters Reuters
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth

Aug 5 (Reuters) - Eli Lilly and Co posted better-than-expected quarterly results and raised its full-year revenue forecast on Wednesday, banking on sustained demand for its blockbuster GLP-1 weight-loss and diabetes drugs, sending its shares up 5% in premarket trading.
Trendline Trendline
Pagaya Technologies Reports Strong Q2 Earnings, Raises 2026 Outlook

Pagaya Technologies Reports Strong Q2 Earnings, Raises 2026 Outlook

Pagaya Technologies Reports Strong Q2 Earnings, Raises 2026 Outlook
Trendline Trendline
Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success

Eli Lilly's Stock Split Consideration Amid Obesity Drug Success
Trendline Trendline
Novo Nordisk Raises 2026 Financial Outlook Amid Strong GLP-1 Sales

Novo Nordisk Raises 2026 Financial Outlook Amid Strong GLP-1 Sales

Novo Nordisk Raises 2026 Financial Outlook Amid Strong GLP-1 Sales
Trendline Trendline
Novo Nordisk Shares Decline After Disappointing Guidance

Novo Nordisk Shares Decline After Disappointing Guidance

Novo Nordisk Shares Decline After Disappointing Guidance
Trendline Trendline
Palantir's Q2 Earnings Exceed Expectations with Strong U.S. Revenue Growth

Palantir's Q2 Earnings Exceed Expectations with Strong U.S. Revenue Growth

Palantir's Q2 Earnings Exceed Expectations with Strong U.S. Revenue Growth
Trendline Trendline
Meta's AI Spending Strategy Faces Investor Skepticism Amid Earnings Report

Meta's AI Spending Strategy Faces Investor Skepticism Amid Earnings Report

Meta's AI Spending Strategy Faces Investor Skepticism Amid Earnings Report